Onconova Therapeutics, Inc. (ONTX) |
|
0.851 -0.014 (-1.66%)
|
01-27 15:59 |
|
Open: |
0.86 |
Pre. Close: |
0.8654 |
|
High:
|
0.8699 |
Low:
|
0.8275 |
|
Volume:
|
74,239 |
Market Cap:
|
18(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:46:51 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 1.07 One year: 1.25 |
| Support: |
Support1: 0.73 Support2: 0.62 |
| Resistance: |
Resistance1: 0.92 Resistance2: 1.07 |
| Pivot: |
0.82  |
| Moving Average: |
MA(5): 0.85 MA(20): 0.78
MA(100): 0.82  MA(250): 1.18 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 70.2 %D(3): 70.6 |
| RSI: |
RSI(14): 58.4 |
| 52-week: |
High: 2.03 Low: 0.62 |
| Average Vol(K): |
3-Month: 84 (K) 10-Days: 69 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ONTX ] has closed below upper band by 38.0%. Bollinger Bands are 0.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.87 - 0.88 |
0.88 - 0.88 |
|
Low:
|
0.82 - 0.82 |
0.82 - 0.83 |
|
Close:
|
0.84 - 0.85 |
0.85 - 0.86 |
|
Company Description |
|
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company develops a Phase Ib/II ISS with rigosertib monotherapy in patients with advanced squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa; and has a preclinical program comprising IV/oral rigosertib for COVID-19. It has a license agreement with SymBio Pharmaceuticals Limited; license, development, and commercialization agreement with Pint International SA.; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania. |
Headline News |
Thu, 26 Jan 2023
Onconova Therapeutics Announces Participation in the Channelchek Takeaway Series - Yahoo Finance
Mon, 23 Jan 2023
Mental health resources across Canada - CTV News
Sun, 22 Jan 2023
Cadrenal Therapeutics Stock (NASDAQ:CVKD), Quotes and News ... - Benzinga
Wed, 07 Dec 2022
Onconova Therapeutics to Present at the Upcoming MedInvest ... - GlobeNewswire
Mon, 28 Nov 2022
Onconova Therapeutics to Present at the Upcoming RHK Capital ... - GlobeNewswire
Mon, 07 Nov 2022
Onconova Therapeutics to Provide Corporate Update and ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
21 (M) |
|
% Held by Insiders
|
2.081e+007 (%) |
|
% Held by Institutions
|
0.4 (%) |
|
Shares Short
|
16 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-1.764e+007 |
|
EPS Est Next Qtl
|
-0.76 |
|
EPS Est This Year
|
-2.86 |
|
EPS Est Next Year
|
-2.1 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-7 |
|
Return on Assets (ttm)
|
812.3 |
|
Return on Equity (ttm)
|
-21.3 |
|
Qtrly Rev. Growth
|
226000 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
-27.25 |
|
EBITDA (p.s.)
|
147712 |
|
Qtrly Earnings Growth
|
-0.9 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-17 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.04 |
|
Price to Cash Flow
|
0.81 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
7290 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2018-09-25 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
